NASDAQ: PAVMPavmed Inc Stock
$1.97+0.10 (+5.35%)
Updated Apr 17, 2024
PAVM Price
$1.97
Fair Value Price
N/A
Market Cap
$18.07M
52 Week Low
$1.60
52 Week High
$9.36
P/E
-0.22x
P/B
-0.34x
P/S
12.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.45M
Earnings
-$64.18M
Gross Margin
-161.8%
Operating Margin
-2,593.23%
Profit Margin
-2,702.7%
Debt to Equity
-1.06
Operating Cash Flow
-$52M
Beta
1.03
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PAVM Overview
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PAVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PAVM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PAVM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PAVM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PAVM due diligence checks available for Premium users.
Be the first to know about important PAVM news, forecast changes, insider trades & much more!
PAVM News
Valuation
PAVM fair value
Fair Value of PAVM stock based on Discounted Cash Flow (DCF)
Price
$1.97
Fair Value
-$0.01
Undervalued by
18,706.98%
PAVM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PAVM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
28.84x
Market
41.64x
PAVM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.34x
Industry
3.66x
PAVM's financial health
Profit margin
Revenue
$1.0M
Net Income
-$14.0M
Profit Margin
-1,516.2%
PAVM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PAVM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$33.1M
Liabilities
$57.1M
Debt to equity
-1.06
PAVM's short-term liabilities ($54.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PAVM's short-term assets ($24.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PAVM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PAVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.9M
Investing
-$183.0k
Financing
$5.3M
PAVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PAVM vs Medical Device Stocks
Pavmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.